Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
KPA pointed importance of 1-year exclusivity
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Dec 15, 2014 08:08:23
Korean Pharmaceutical Association (KPA) emphasized that the government should allow generic drugmakers who invalidate patents on brand-name drugs to have the privilege on marketing of their first generic version.

KPA had a press conference on December 10 to insist that the marketing privilege will help generic drugmakers enter the market more quickly, fighting against multinational pharmaceutical companies.

It is known that a congressman is about to make a proposal that the article about allowing marketing privileges for the first generic drug maker should be removed.

Pharmaceutical companies pointed that patients will pay less and have more options when generic drugs are available as early as possible and the government can cut healthcare spending while motivating pharmaceutical companies to develop their own technologies.

According to the article enacted with the patent-approval linkage system on March 15, 2015, the first generic drug maker who invalidates the patent on a brand-name drug has a one-year period of marketing exclusivity.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com